BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
latest_posts
- 1
Israel's ban on unsupervised reporters in Gaza causes strategic harm to legitimacy - 25 Most Expected Film Delivery
- 3Scientists document a death from a meat allergy tied to certain ticks
- 4Northern lights chances rise for Christmas as space weather remains unsettled
- 5Iconic iceberg turns blue, on verge of totally disintegrating, NASA says
- Share your pick for the tree that you love for its novel magnificence!
- Ukraine Now Using Drone Boats To Attack Russian Riverine Targets
- Finding China: Four Urban areas for a Remarkable Excursion
- Flu season is underway. What are common symptoms to watch for?
- Trump announces 'Patriot Games' with 2 competitors from every state and territory: What we know
- The Best 15 Applications for Efficiency and Association
- Islamic State group militants claim capture and execution of a Nigerian brigadier general
- Poland open to German troops to help secure Ukraine ceasefire
- Rediscovering Imagination in Adulthood: Individual Creative Excursions
